Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06062069 · ClinicalTrials.gov registry record · Phase 2
A Study of CT-868 in Type 1 Diabetes Mellitus
A Phase 2 study, sponsored by Carmot Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
NCT06062069: Completed Phase 2 study, sponsored by Carmot Therapeutics.
NCT06062069 is a Phase 2 study that has completed, run by Carmot Therapeutics. The registered enrollment target is 111 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06062069, a Phase 2 study, has completed, sponsored by Carmot Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
Study Summary
This study will evaluate the changes in glycemic control in overweight and obese adults with Type 1 Diabetes Mellitus after receiving CT-868 for 16 weeks. The effectiveness and safety of CT-868 will be compared to placebo. All participants will continue with their standard diabetes care using either an insulin pump (CSII) or multiple daily injections (MDI). Alongside their designated treatment, participants will receive guidance on managing their diabetes, including monitoring blood glucose levels and diet and exercise recommendations. Treatment assignments, either CT-868 plus insulin or placebo plus insulin will be randomly determined.
Interventions
- DRUG CT-868
- DEVICE CT-868 Pen Injector
- DRUG CT-868 Pen Injector, Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2023-10-19 |
| Est. Completion | 2025-07-09 |
| Phase | Phase 2 |
What the finished NCT06062069 record still lists
NCT06062069 is an interventional study that assigns participants to a tested intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% lower).
The record links to 0 conditions, and to 3 interventions - of which CT-868 is the first listed.
NCT06062069 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06062069 about?
NCT06062069 is a clinical study titled "A Study of CT-868 in Type 1 Diabetes Mellitus". This study will evaluate the changes in glycemic control in overweight and obese adults with Type 1 Diabetes Mellitus after receiving CT-868 for 16 weeks. The effectiveness and safety of CT-868 will be compared to placebo. All participants will continue with their standard diabetes care using either...
What is the current status of trial NCT06062069?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2023-10-19. Estimated completion is 2025-07-09.
What interventions are being tested in trial NCT06062069?
The interventions under investigation include: CT-868 (DRUG), CT-868 Pen Injector (DEVICE), CT-868 Pen Injector, Placebo (DRUG).
Who is sponsoring clinical trial NCT06062069?
This trial is sponsored by Carmot Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06062069's enrollment target sits among peer trials
111 632nd of 2000 higher than 1,369 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI